RXRG and prostate cancer: Associations werefound with metastatic cancer (12/6; gains/losses), localized high (1/4;gain/losses) and low risk (1 loss; RXRG), prostateintraepithelial neoplasia (PIN) (2/1; gains/loss) (Kim et al., 2007), and with theintermediate risk prostate cancer (6 losses) (Ishkanian et al., 2009).